KPV 10 mg — Inflammation & Cellular Response Research
KPV (Lys-Pro-Val) is a short peptide fragment derived from α-melanocyte-stimulating hormone (α-MSH). It is studied in preclinical research for its potential influence on inflammatory signaling, immune-response pathways, intestinal epithelial integrity, and tissue repair.
Researchers have investigated KPV in experimental models involving NF-κB-associated inflammatory pathways, cytokine activity, gut inflammation, and cellular responses to injury.
For laboratory and research use only. Not for human consumption.
KPV 10 mg — Inflammation & Cellular Response Research
KPV (Lys-Pro-Val) is a short peptide fragment derived from α-melanocyte-stimulating hormone (α-MSH). It is studied in preclinical research for its potential influence on inflammatory signaling, immune-response pathways, intestinal epithelial integrity, and tissue repair.
Researchers have investigated KPV in experimental models involving NF-κB-associated inflammatory pathways, cytokine activity, gut inflammation, and cellular responses to injury.
For laboratory and research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
